News
First living tissue 3D printed in space aboard International Space Station
Using the “Organaut”, a 3D bioprinter designed for microgravity, Russia has become the first country to print living tissue in space. After a December 3rd cargo delivery to the International Space Station (ISS), cosmonaut Oleg Kononenko completed an experiment with the machine in the Russian sector of the station, successfully producing human cartilage tissue and a rodent thyroid gland. The Organaut was designed via a collaboration with the printer’s maker, 3D Bioprinting Solutions, and Russia’s national space agency, Roscosmos. The United States also has its own bioprinting mission scheduled for the first half of 2019, joining in the march to develop biological solutions for problems that space is well suited to solve.
A 3D bioprinter operates by creating one layer at a time of specified tissue or stem cell material arranged as needed to grow and form as biologically programmed to do. As summarized by Aryeh Batt, the CEO of Precise Bio, a company dedicated to 3D printed bioproducts for human eyes, “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.” In the case of Organaut, an internal robotic mechanism drips living cell fabric layers from an automatic syringe. When living tissue is bioprinted under Earth’s gravity, the artificial cells grow in a flatter structure than their natural state in the human body. In microgravity, however, they form a shape closer to their normal dimensions.
Along with demonstrating the growth advantages of microgravity, Organaut’s tissue samples will provide the ability to study the effect of radiation on the body. “We will look at how the constructs came together, and how they behaved,” confirmed Usef Hesuani, head of laboratory projects and a managing partner of 3D Bioprinting Solutions in a recent press conference. The original Organaut printer was aboard the Soyuz MS-10 spacecraft which experienced an launch failure on October 11, 2018, forcing the U.S. and Russian crew to make an emergency landing. A second one was quickly put together for the subsequent mission.
The parent company of 3D Bioprinting Solutions is INVITRO, the largest private medical company in Russia. Founded in 1995 by Aleksandr Ostrovsky, it has 8 laboratories and over 1000 medical offices in eastern Europe, but is primarily based in Skolkovo, a high technology business area in Moscow. Bioprinting Solutions made headlines in 2015 when it printed and transplanted a functioning mouse thyroid gland. The experiment performed aboard the ISS with Organaut was a modified version of their prior work.
Unlike NASA, Roscosmos does not generally partner with private companies for its research endeavors. In an effort to inspire Russian students to enter STEM fields within their country, the agency sought to spotlight the developing bioprinting industry by using the Organaut. The successful partnership with 3D Bioprinting Solutions has now motivated the agency to continue partnering with private companies in the future. The company itself also sees advantages to collaborations of its own with other Skolkova-area manufacturers. “We have companies that are making satellite platforms…it is possible to conduct a similar experiment amid microgravity on small spacecraft [like satellites]…smaller and cheaper,” noted Ivan Kosenkov, 3D Bioprinting Solutions’ project manager.
Organaut’s printed tissues were returned to Earth with the Soyuz MS-09 spacecraft on December 20th, and the results of the experiment are expected to be published at the end of January 2019. In February, NASA plans to send a bioprinter capable of producing beating heart tissue to the ISS. Named the 3D BioFabrication Facility (BFF), the machine was developed through a partnership with two companies well-established in 3D printing and on-orbit hardware, nScrypt and Techshot. Since the thickness of heart tissue is difficult to build under gravity without structural assistance that could impede functionality, the companies developed the BFF with the hypothesis that microgravity would overcome this limitation. Thus far, the concept has been proven during parabolic flight tests, i.e., aboard the “Vomit Comet” airplane that performs multiple parabolic maneuvers in an airliner to create 20-30 seconds of weightlessness each.
Elon Musk
SpaceX issues statement on Starship V3 Booster 18 anomaly
The incident unfolded during gas-system pressure testing at the company’s Massey facility in Starbase, Texas.
SpaceX has issued an initial statement about Starship Booster 18’s anomaly early Friday. The incident unfolded during gas-system pressure testing at the company’s Massey facility in Starbase, Texas.
SpaceX’s initial comment
As per SpaceX in a post on its official account on social media platform X, Booster 18 was undergoing gas system pressure tests when the anomaly happened. Despite the nature of the incident, the company emphasized that no propellant was loaded, no engines were installed, and personnel were kept at a safe distance from the booster, resulting in zero injuries.
“Booster 18 suffered an anomaly during gas system pressure testing that we were conducting in advance of structural proof testing. No propellant was on the vehicle, and engines were not yet installed. The teams need time to investigate before we are confident of the cause. No one was injured as we maintain a safe distance for personnel during this type of testing. The site remains clear and we are working plans to safely reenter the site,” SpaceX wrote in its post on X.
Incident and aftermath
Livestream footage from LabPadre showed Booster 18’s lower half crumpling around the liquid oxygen tank area at approximately 4:04 a.m. CT. Subsequent images posted by on-site observers revealed extensive deformation across the booster’s lower structure. Needless to say, spaceflight observers have noted that Booster 18 would likely be a complete loss due to its anomaly.
Booster 18 had rolled out only a day earlier and was one of the first vehicles in the Starship V3 program. The V3 series incorporates structural reinforcements and reliability upgrades intended to prepare Starship for rapid-reuse testing and eventual tower-catch operations. Elon Musk has been optimistic about Starship V3, previously noting on X that the spacecraft might be able to complete initial missions to Mars.
Investor's Corner
Tesla analyst maintains $500 PT, says FSD drives better than humans now
The team also met with Tesla leaders for more than an hour to discuss autonomy, chip development, and upcoming deployment plans.
Tesla (NASDAQ:TSLA) received fresh support from Piper Sandler this week after analysts toured the Fremont Factory and tested the company’s latest Full Self-Driving software. The firm reaffirmed its $500 price target, stating that FSD V14 delivered a notably smooth robotaxi demonstration and may already perform at levels comparable to, if not better than, average human drivers.
The team also met with Tesla leaders for more than an hour to discuss autonomy, chip development, and upcoming deployment plans.
Analysts highlight autonomy progress
During more than 75 minutes of focused discussions, analysts reportedly focused on FSD v14’s updates. Piper Sandler’s team pointed to meaningful strides in perception, object handling, and overall ride smoothness during the robotaxi demo.
The visit also included discussions on updates to Tesla’s in-house chip initiatives, its Optimus program, and the growth of the company’s battery storage business. Analysts noted that Tesla continues refining cost structures and capital expenditure expectations, which are key elements in future margin recovery, as noted in a Yahoo Finance report.
Analyst Alexander Potter noted that “we think FSD is a truly impressive product that is (probably) already better at driving than the average American.” This conclusion was strengthened by what he described as a “flawless robotaxi ride to the hotel.”
Street targets diverge on TSLA
While Piper Sandler stands by its $500 target, it is not the highest estimate on the Street. Wedbush, for one, has a $600 per share price target for TSLA stock.
Other institutions have also weighed in on TSLA stock as of late. HSBC reiterated a Reduce rating with a $131 target, citing a gap between earnings fundamentals and the company’s market value. By contrast, TD Cowen maintained a Buy rating and a $509 target, pointing to strong autonomous driving demonstrations in Austin and the pace of software-driven improvements.
Stifel analysts also lifted their price target for Tesla to $508 per share over the company’s ongoing robotaxi and FSD programs.
Elon Musk
SpaceX Starship Version 3 booster crumples in early testing
Photos of the incident’s aftermath suggest that Booster 18 will likely be retired.
SpaceX’s new Starship first-stage booster, Booster 18, suffered major damage early Friday during its first round of testing in Starbase, Texas, just one day after rolling out of the factory.
Based on videos of the incident, the lower section of the rocket booster appeared to crumple during a pressurization test. Photos of the incident’s aftermath suggest that Booster 18 will likely be retired.
Booster test failure
SpaceX began structural and propellant-system verification tests on Booster 18 Thursday night at the Massey’s Test Site, only a few miles from Starbase’s production facilities, as noted in an Ars Technica report. At 4:04 a.m. CT on Friday, a livestream from LabPadre Space captured the booster’s lower half experiencing a sudden destructive event around its liquid oxygen tank section. Post-incident images, shared on X by @StarshipGazer, showed notable deformation in the booster’s lower structure.
Neither SpaceX nor Elon Musk had commented as of Friday morning, but the vehicle’s condition suggests it is likely a complete loss. This is quite unfortunate, as Booster 18 is already part of the Starship V3 program, which includes design fixes and upgrades intended to improve reliability. While SpaceX maintains a rather rapid Starship production line in Starbase, Booster 18 was generally expected to validate the improvements implemented in the V3 program.
Tight deadlines
SpaceX needs Starship boosters and upper stages to begin demonstrating rapid reuse, tower catches, and early operational Starlink missions over the next two years. More critically, NASA’s Artemis program depends on an on-orbit refueling test in the second half of 2026, a requirement for the vehicle’s expected crewed lunar landing around 2028.
While SpaceX is known for diagnosing failures quickly and returning to testing at unmatched speed, losing the newest-generation booster at the very start of its campaign highlights the immense challenge involved in scaling Starship into a reliable, high-cadence launch system. SpaceX, however, is known for getting things done quickly, so it would not be a surprise if the company manages to figure out what happened to Booster 18 in the near future.
SpaceX issues statement on Starship V3 Booster 18 anomaly
Tesla analyst maintains $500 PT, says FSD drives better than humans now
